This might suggest that even the high mutation burden subset of melanoma, which shows over-expression of both IDO-1 and IDO-2 but not TDO-2, does not respond to IDO-1 inhibitors and over-expression of all three genes are necessary for response to IDO-1 inhibitors. The gene discussed is TDO2; the disease is melanoma.